dihydrouracil has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 14 studies
hexahydropyrimidine-2,4-dione: structure in first source
5,6-dihydrouracil : A pyrimidine obtained by formal addition of hydrogen across the 5,6-position of uracil.
Dihydropyrimidine Dehydrogenase Deficiency: An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity." | 1.46 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. ( Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E, 2017) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Marin, C | 1 |
| Krache, A | 1 |
| Palmaro, C | 1 |
| Lucas, M | 1 |
| Hilaire, V | 1 |
| Ugdonne, R | 1 |
| De Victor, B | 1 |
| Quaranta, S | 1 |
| Solas, C | 1 |
| Lacarelle, B | 2 |
| Ciccolini, J | 2 |
| García-González, X | 1 |
| Kaczmarczyk, B | 1 |
| Abarca-Zabalía, J | 1 |
| Thomas, F | 2 |
| García-Alfonso, P | 1 |
| Robles, L | 1 |
| Pachón, V | 1 |
| Vaz, Á | 1 |
| Salvador-Martín, S | 1 |
| Sanjurjo-Sáez, M | 1 |
| López-Fernández, LA | 1 |
| Meulendijks, D | 2 |
| Henricks, LM | 2 |
| Jacobs, BAW | 1 |
| Aliev, A | 1 |
| Deenen, MJ | 1 |
| de Vries, N | 2 |
| Rosing, H | 2 |
| van Werkhoven, E | 1 |
| de Boer, A | 1 |
| Beijnen, JH | 2 |
| Mandigers, CMPW | 1 |
| Soesan, M | 1 |
| Cats, A | 1 |
| Schellens, JHM | 1 |
| Yeung, CW | 1 |
| Yau, MM | 1 |
| Ma, CK | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Lam, CW | 1 |
| van Staveren, MC | 2 |
| Opdam, F | 1 |
| Guchelaar, HJ | 2 |
| van Kuilenburg, AB | 3 |
| Maring, JG | 2 |
| Gelderblom, H | 2 |
| Hennebelle, I | 1 |
| Delmas, C | 1 |
| Lochon, I | 1 |
| Dhelens, C | 1 |
| Garnier Tixidre, C | 1 |
| Bonadona, A | 1 |
| Penel, N | 1 |
| Goncalves, A | 1 |
| Delord, JP | 1 |
| Toulas, C | 1 |
| Chatelut, E | 1 |
| Meijer, J | 1 |
| Punt, CJ | 1 |
| de Jong, RS | 1 |
| Jacobs, BA | 1 |
| Schellens, JH | 1 |
| Ben Fredj, R | 1 |
| Gross, E | 2 |
| Ben Ahmed, S | 1 |
| Hassine, H | 1 |
| Saguem, S | 1 |
| Mounier-Boutoille, H | 1 |
| Boisdron-Celle, M | 2 |
| Cauchin, E | 1 |
| Galmiche, JP | 1 |
| Morel, A | 2 |
| Gamelin, E | 2 |
| Matysiak-Budnik, T | 1 |
| Weidensee, S | 1 |
| Goettig, P | 1 |
| Bertone, M | 1 |
| Haas, D | 1 |
| Magdolen, V | 1 |
| Kiechle, M | 1 |
| Meindl, A | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Oliver, M | 1 |
| Mercier, C | 1 |
| Peytel, E | 1 |
| Wettergren, Y | 1 |
| Carlsson, G | 1 |
| Odin, E | 1 |
| Gustavsson, B | 1 |
| Remaud, G | 1 |
| Traore, S | 1 |
| Poirier, AL | 1 |
| Gamelin, L | 1 |
1 trial available for dihydrouracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
Topics: Administration, Oral; Case-Control Studies; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouraci | 2016 |
13 other studies available for dihydrouracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatog | 2020 |
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Computer Simulation; | 2020 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
Diagnosis of dihydropyrimidinase deficiency in a Chinese boy with dihydropyrimidinuria.
Topics: Child, Preschool; China; Dihydropyrimidine Dehydrogenase Deficiency; Hong Kong; Humans; Male; Metabo | 2013 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Topics: Adult; Antimetabolites, Antineoplastic; Biotransformation; Dihydropyrimidine Dehydrogenase Deficienc | 2016 |
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
Topics: Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehy | 2016 |
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Chromatography, High Pressure Liquid; Colo | 2009 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.
Topics: Amino Acid Sequence; Child; Creatinine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil De | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2007 |